To test our hypothesis, we examined the bioenergetic profiles of z-VRPR-fmk- or vehicle-treated DLBCL cells, after confirming z-VRPR-fmk efficiently blocked the proteolytic activity of MALT1 (Supplementary Figure 1A). The gene discussed is MALT1; the disease is diffuse large B-cell lymphoma.